The Lancet Oncology in conversation with

Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer

August 30, 2022 The Lancet Oncology
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
The Lancet Oncology in conversation with
More Info
The Lancet Oncology in conversation with
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
Aug 30, 2022
The Lancet Oncology

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.

Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Show Notes

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.

Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv